BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk

URN to cite this document:: urn:nbn:de:bvb:355-epub-353437
DOI to cite this document:: 10.5283/epub.35343

Spurdle, A. B. ; Whiley, P. J. ; Thompson, B. ; Feng, B. ; Healey, S. ; Brown, M. A. ; Pettigrew, C. ; kConFab, . ; Van Asperen, C. J. ; Weber, Bernhard H. F.

; Dutch Belgium UV Consortium, . ; German Consortium of Hereditary Breast and Ovarian Cancer, . ; French COVAR group collaborators, . ; on behalf of the ENIGMA Consortium, .

Preview

License: Allianz- bzw. Nationallizenz
PDF - Published Version
(212kB)

Date of publication of this fulltext: 24 Mar 2017 09:48

Alternative links to fulltext:DOI Pubmed Central Pubmed

Details

Preview

Export bibliographical data

Abstract

Background Clinical classification of rare sequence changes identified in the breast cancer susceptibility genes BRCA1 and BRCA2 is essential for appropriate genetic counselling of individuals carrying these variants. We previously showed that variant BRCA1 c.5096G>A p.Arg1699Gln in the BRCA1 transcriptional transactivation domain demonstrated equivocal results from a series of functional assays, ...